Efavirenz 600mg + Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg Tablet is a fixed-dose combination antiretroviral medicine used as part of HIV-1 treatment. The combination contains three antiretroviral agents from two drug classes: efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), and lamivudine plus tenofovir disoproxil fumarate (TDF), which are nucleoside/nucleotide reverse transcriptase inhibitors.
The 600mg/300mg/300mg formulation is an established fixed-dose combination. The NIH identifies the combination as efavirenz/lamivudine/tenofovir disoproxil fumarate (EFV/3TC/TDF), with 600mg/300mg/300mg tablets available under the brand reference Symfi. WHO has also prequalified multiple 600mg/300mg/300mg film-coated products, including products from manufacturers such as Mylan, Hetero, Laurus and Desano.
Efavirenz/lamivudine/tenofovir DF is used as part of antiretroviral therapy for HIV-1 infection.
The three active ingredients work at different points within the HIV reverse-transcription process:
Combining these agents provides a multi-drug antiretroviral regimen designed to suppress HIV replication.
The three active ingredients are combined into one tablet at the following strengths:
| Active Ingredient | Amount per Tablet | Class |
|---|---|---|
| Efavirenz | 600mg | NNRTI |
| Lamivudine | 300mg | NRTI |
| Tenofovir Disoproxil Fumarate | 300mg | NRTI |
The FDA-linked prescribing information specifically identifies the 600mg/300mg/300mg product as a fixed-dose combination of these three antiretroviral drugs.
HIV requires the enzyme reverse transcriptase to convert its RNA genetic material into DNA.
Efavirenz, lamivudine and tenofovir interfere with this process through complementary mechanisms.
Efavirenz directly inhibits HIV reverse transcriptase as an NNRTI. Lamivudine and tenofovir interfere with viral DNA synthesis as NRTI/NtRTI agents.
The combined effect reduces HIV replication when the regimen is taken consistently as prescribed.
Efavirenz lamivudine tenofovir for HIV is the principal treatment-related search cluster for this product.
The fixed-dose formulation provides three antiretroviral agents in one tablet and may simplify treatment compared with taking the individual medicines separately.
However, contemporary HIV treatment is individualized. The most appropriate antiretroviral regimen depends on factors including resistance testing, previous treatment, viral load, CD4 count, drug interactions, kidney function, hepatitis B status, pregnancy considerations and other clinical factors.
This distinction is important for SEO and product accuracy.
Atripla® is not the same three-drug combination.
Atripla contains:
The product in this listing contains:
Therefore, Efavirenz/Lamivudine/Tenofovir 600/300/300mg should not be described as generic Atripla. Current drug references confirm the distinction between Atripla’s efavirenz/emtricitabine/tenofovir formulation and the efavirenz/lamivudine/tenofovir combination.
Symfi® is the relevant US brand reference for the 600mg/300mg/300mg combination.
The NIH lists Symfi as a brand name for efavirenz/lamivudine/tenofovir disoproxil fumarate 600mg/300mg/300mg.
Where a particular product has the appropriate regulatory status, commercially relevant search terms include:
Generic Symfi → Efavirenz Lamivudine Tenofovir 600/300/300mg → EFV/3TC/TDF 600/300/300mg
Use “Generic Symfi” only where the specific product is legally authorized and marketed as a generic/equivalent product in the relevant target market.
Symfi and Symfi Lo are related products but have different efavirenz strengths.
The 600/300/300mg formulation corresponds to Symfi, whereas Symfi Lo uses a lower efavirenz strength. The NIH lists both formulations under efavirenz/lamivudine/tenofovir DF.
For this product, the correct strength-specific commercial relationship is:
Efavirenz 600mg + Lamivudine 300mg + Tenofovir DF 300mg → Symfi 600/300/300mg
The appropriate dose and treatment regimen must be determined by the prescribing HIV specialist.
The NIH patient information identifies the 600mg/300mg/300mg formulation as an oral tablet and instructs patients to take it according to their healthcare provider’s directions.
For the specific 600/300/300mg fixed-dose product, treatment decisions should take into account renal function, hepatic status, concurrent medicines, HIV resistance history and hepatitis B status.
Do not start, stop or change antiretroviral treatment without medical supervision.
The NIH patient information states that efavirenz/lamivudine/tenofovir DF should be taken according to the healthcare provider’s instructions and notes that it is taken on an empty stomach, preferably at bedtime. Bedtime administration may help reduce the impact of some efavirenz-related nervous-system effects.
The tablet should be taken consistently according to the prescribed regimen.
Missing antiretroviral doses can reduce treatment effectiveness and may contribute to development of drug resistance.
Potential adverse effects may include:
The combination can also be associated with clinically important renal, hepatic, bone and metabolic effects, particularly because tenofovir DF requires attention to kidney function and efavirenz can cause central nervous system and psychiatric adverse effects.
Seek medical advice promptly if severe or persistent adverse effects occur.
Efavirenz can cause central nervous system effects such as:
These effects can be more noticeable when treatment is first started and may improve with continued treatment in some patients.
Avoid driving or operating machinery if you experience dizziness, impaired concentration or other effects that could affect alertness.
Tenofovir disoproxil fumarate can affect kidney function.
Renal function should be assessed before and during treatment according to clinical guidance. Patients with existing kidney disease or other risk factors for renal toxicity may require an alternative regimen or closer monitoring.
The appropriate use of the fixed-dose combination depends partly on whether the patient’s renal function is suitable for the tenofovir DF component.
Tenofovir DF may affect bone mineral density in some patients.
Healthcare professionals may consider bone health and individual risk factors when selecting and monitoring antiretroviral therapy.
Lamivudine and tenofovir have activity against hepatitis B virus (HBV).
Patients with HIV should be evaluated for HBV infection before treatment where clinically appropriate. Stopping medicines with anti-HBV activity can result in a hepatitis B flare in patients with HBV infection.
Do not discontinue this combination without medical supervision.
Efavirenz is associated with clinically significant drug interactions because it affects several drug-metabolizing pathways.
The combination may interact with medicines including certain:
Patients should provide their healthcare professional with a complete list of medicines and supplements before starting treatment.
Pregnancy and reproductive considerations should be discussed with an HIV specialist before treatment.
Modern HIV guidelines take pregnancy status, potential pregnancy and reproductive plans into account when selecting antiretroviral therapy.
Do not change an effective HIV regimen because of pregnancy without speaking with the treating clinician.
Efavirenz Lamivudine Tenofovir 600/300/300mg Tablet has strong commercial product intent around HIV antiretroviral treatment.
Relevant product searches include:
Efavirenz Lamivudine Tenofovir 600/300/300mg, Efavirenz 600mg Lamivudine 300mg Tenofovir 300mg, EFV/3TC/TDF 600/300/300mg, Generic Symfi 600/300/300mg, Symfi Generic, Efavirenz Lamivudine Tenofovir Tablet, HIV Fixed Dose Combination Tablet, HIV Antiretroviral Combination, HIV Treatment Tablet and EFV 3TC TDF Tablet.
WHO has prequalified multiple manufacturers of the 600mg/300mg/300mg film-coated formulation, demonstrating that this is an established fixed-dose pharmaceutical product rather than a formulation associated only with one brand.
Prescription requirements, approved products, manufacturer availability, import regulations and treatment guidelines vary between the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
It is a fixed-dose antiretroviral tablet containing efavirenz 600mg, lamivudine 300mg and tenofovir disoproxil fumarate 300mg.
It is used as part of antiretroviral treatment for HIV-1 infection.
The 600/300/300mg formulation corresponds to the active ingredients and strengths in Symfi. A specific product should be called generic Symfi only where its regulatory status supports that claim.
No. Atripla contains efavirenz, emtricitabine and tenofovir DF, whereas this product contains efavirenz, lamivudine and tenofovir DF.
No. Lamivudine and emtricitabine are different active pharmaceutical ingredients, although both belong to the NRTI class and have related pharmacological characteristics.
EFV means efavirenz, 3TC means lamivudine and TDF means tenofovir disoproxil fumarate.
Each tablet contains efavirenz 600mg + lamivudine 300mg + tenofovir disoproxil fumarate 300mg.
The active ingredients are generic antiretroviral medicines, and WHO has prequalified multiple 600/300/300mg products. Whether a particular product can legally be described as a generic of a named reference brand depends on its regulatory status in the target country. Vonaday / Tenolam E / Trioday / Avonza
Antiretroviral treatment should not be stopped without medical advice. Stopping treatment can allow HIV viral replication to increase and may contribute to resistance. Patients with hepatitis B may also face a risk of HBV reactivation or flare when anti-HBV-active medicines are discontinued.
No. Antiretroviral therapy suppresses HIV replication and helps maintain immune function, but it does not eradicate HIV from the body.
The 600/300/300mg formulation has been WHO-prequalified from multiple manufacturers and is available in international HIV treatment supply chains. Availability and regulatory requirements vary by country.
It is a prescription antiretroviral medicine. Online purchases should be made only through appropriately licensed pharmacies or authorized pharmaceutical suppliers and in accordance with local regulations.
Follow the instructions supplied with your product or from your HIV clinician. Do not routinely double the next dose. The NIH advises taking a missed dose when remembered unless it is almost time for the next dose, in which case the missed dose should be skipped.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Efavirenz/lamivudine/tenofovir disoproxil fumarate is a prescription antiretroviral combination that should be selected and monitored by a qualified HIV healthcare professional. Kidney function, liver function, hepatitis B status, pregnancy considerations, HIV resistance history and drug interactions may affect treatment selection. Do not start, stop or change antiretroviral therapy without medical supervision.
Last Updated: August 25, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.